AAP
ANIP icon

Arax Advisory Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Arax Advisory Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6K Sell
345
-685
-67% -$55K ﹤0.01% 3705
2026
Q1 		$9.86K Buy
1,030
+903
+711% +$70.5K ﹤0.01% 2447
2025
Q4 		$10K Sell
127
-224
-64% -$19.4K ﹤0.01% 2468
2025
Q3 		$32.2K Buy
351
+227
+183% +$18.5K ﹤0.01% 2057
2025
Q2 		$8.09K Buy
+124
New +$8.07K ﹤0.01% 2060

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's ANIP Position: Q2 2026 in Review

Arax Advisory Partners reduced its ANI Pharmaceuticals (ANIP) stake by 67% in Q2 2026, selling an estimated $55K and leaving 345 shares worth $28.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3705.

Arax Advisory Partners first reported a position in ANIP in Q2 2025 and has held it in 5 quarters since. The position peaked at $32.2K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Arax Advisory Partners held 345 shares of ANI Pharmaceuticals worth $28.6K as of Q2 2026.
  • Arax Advisory Partners sold 685 ANI Pharmaceuticals shares in Q2 2026, an estimated $55K.
  • ANI Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3705 holding.
  • Arax Advisory Partners first reported a position in ANI Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Arax Advisory Partners's ANI Pharmaceuticals position peaked at $32.2K in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.